Phaseline

Companies › R1 Therapeutics

R1 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AP306
Phosphate binder
–Phase 2HyperphosphatemiaFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06712654AP306Phase 2HyperphosphatemiaGenitourinaryFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Tioga Pharmaceuticals Azure Biotech Gesynta Pharma Suzhou Sanegene Bio Prokrea BCN

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.